Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- PMDA Cuts Fees for Pediatric, Orphan Drug Consultations
May 30, 2024
- LDP Lawmakers’ League on Generics Prods Minister to Rethink Off-Year Revisions
May 29, 2024
- Health Minister Acknowledges Changes after 2016 Decision on Off-Year Revisions
May 28, 2024
- MHLW Panel OKs Avigan for SFTS with Strings Attached, Shionogi COVID Jab Only for Primary Use
May 27, 2024
- LDP’s Social Security Commission Urges Govt to Revisit Off-Year Drug Price Revisions
May 24, 2024
- MHLW Proposes Inclusion of Prevenar 20 in National Immunization for Children
May 24, 2024
- MHLW Panel Draws Up Plans for Generic Industry Shakeup in Final Report
May 23, 2024
- Japan Govt to Launch Public-Private Forum to Attract Investments
May 23, 2024
- No Inclusion of Males in National HPV Vaccinations for Now: MHLW Panel
May 23, 2024
- Japan to Survey Uneven Distribution of Yakkasa, Look into Voluntary Chain Deals Too
May 23, 2024
- Fresh Panel Discussion for Avigan’s SFTS Use Set for May 24
May 23, 2024
- LDP Project Team Finalizes Proposal, Pushes Rethink of Off-Year Revisions
May 22, 2024
- MOF Panel Urges Full-Scale Off-Year Revisions, Enhanced CEA: “Spring” Proposal
May 22, 2024
- Off-Year Price Revisions Should Either Be Abolished or Revisited: LDP Lawmakers
May 21, 2024
- Bridion Sees Rare May Generic Entry for New Dosage Form in Japan
May 21, 2024
- Japan’s 1st Stelara Biosimilar Gets Listing, New Kit Products Too
May 21, 2024
- JPA Wary of FPMAJ Pitch to Allow Non-Pharmacists as Drug Production Managers
May 21, 2024
- Allow Use of OOS Autologous Cell Products via PMD Act Amendment: FIRM
May 21, 2024
- Pharma Industry Wants “Internationally Harmonized” Rules under PMD Act
May 20, 2024
- Novartis’ Fabhalta, Novo’s Awiqli, and More Up for PAFSC Review on May 31
May 20, 2024
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…